Clinical Trial Update: Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial sponsored by Mayo Clinic is evaluating autologous adipose-derived mesenchymal stem cells to reduce hemodialysis arteriovenous fistula f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Autologous adipose-derived mesenchymal stem cells (AMSC) (adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Mayo Clinic | Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication | Phase 1 | Status: ACTIVE_NOT_RECRUITING